United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

profile pharma ltd - safinamide methansulfonate - tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

profile pharma ltd - safinamide methansulfonate - tablet - 50mg

Singapore - English - HSA (Health Sciences Authority)

ziwell medical (s) pte ltd - pefloxacin methansulfonate eqv pefloxacin - tablet, film coated - 400 mg - pefloxacin methansulfonate eqv pefloxacin 400 mg

Philippines - English - FDA (Food And Drug Administration)

compania j.m., inc. - tiamulin , colistin methansulfonate - solution for injection (im) - 100mg/ 180,000 i.u./ ml

European Union - English - EMA (European Medicines Agency)

zambon spa - safinamide methanesulfonate - parkinson disease - anti-parkinson drugs - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.

Canada - English - Health Canada

astrazeneca canada inc - osimertinib (osimertinib mesylate) - tablet - 40mg - osimertinib (osimertinib mesylate) 40mg - antineoplastic agents

Canada - English - Health Canada

astrazeneca canada inc - osimertinib (osimertinib mesylate) - tablet - 80mg - osimertinib (osimertinib mesylate) 80mg - antineoplastic agents

Israel - English - Ministry of Health

medison pharma ltd - safinamide as methanesulfonate - film coated tablets - safinamide as methanesulfonate 100 mg - safinamide - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.

Israel - English - Ministry of Health

medison pharma ltd - safinamide as methanesulfonate - film coated tablets - safinamide as methanesulfonate 50 mg - safinamide - xadago is indicated for the treatment of adult patients with idiopathic parkinson’s disease (pd) as add-on therapy to a stable dose of levodopa (l-dopa) alone or in combination with other pd medicinal products in mid-to late-stage fluctuating patients.

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals inc - tricaine methanesulfonate (unii: 971zm8ipk1) (tricaine - unii:02591phl19) - tricaine methanesulfonate 1 kg in 1 kg